Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Inverna Therapeutics ApS
APS
Active
CVR 45161641
Cortex Park 26E, 5230
Odense M
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2024 · 1 year old
— employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Inverna Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
0M
1M
1M
1M
0M
2024
-14M
2025
EBITDA
DKK millions
0M
-4M
-9M
-13M
-18M
0M
2024
-14M
-1400%
2025
Income statement
DKK thousands
Item
2024
2025
Gross profit
—
-14.150
Staff expenses
-0
-0
EBITDA
-159
-14.150
Depreciation & amort.
-0
-0
EBIT
-159
-14.150
Net financials
0
-3
Profit before tax
-159
-14.153
Tax
-0
-2.907
Net profit
-159
-11.246
Balance sheet
DKK thousands
Item
2024
2025
Total assets
3.802
6.949
Equity
3.606
3.814
Long-term debt
0
0
Short-term debt
196
3.135
Total debt
196
3.135
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-1415001900.0%
This company
2024
2025
Equity ratio
54.9%
This company
38.2%
Market median
+44% vs market
2024
2025
Return on equity
-294.9%
This company
18.4%
Market median
-1703% vs market
2024
2025
Net profit margin (of gross profit)
-1124598400.0%
This company
2024
2025
Asset turnover (of gross profit)
-2.04×
This company
2024
2025
Debt / equity
0.82×
This company
0.62×
Market median
+32% vs market
2024
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-10-22 – 2024-12-31
View
PDF
More on Inverna Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
